Dr Yotis Senis was awarded a BScH in Life Sciences in 1993, an MSc in 1996 and a PhD in 2002 in Pathology, Queen’s University, Canada. His PhD under the supervision of Professor Peter Greer was on the regulation of haematopoiesis by the tyrosine kinases Fps and Fer. His postdoctoral training was in the laboratory of Professor Steve Watson, Pharmacology, University of Oxford, UK (2002-2003), characterizing novel receptors and signalling pathways regulating platelet activation and thrombosis. In 2003 he was appointed British Heart Foundation (BHF) Research Fellow in the Birmingham Platelet Group, University of Birmingham, UK, where he developed a keen interest in platelet tyrosine phosphatases, particularly the receptor-type tyrosine phosphatase PTPRJ and how it regulates Src family kinases (SFKs). He was awarded a BHF Intermediate Basic Science Research Fellowship in 2009 and a Senior Fellowship in 2013, investigating the co-inhibitory receptor G6b-B and tyrosine phosphatases Shp1 and Shp2. He was promoted to Chair in Cellular Haemostasis at the University of Birmingham in 2013. In 2019 he was appointed director of research at Etablissement Français du Sang, Inserm UMR-S1255 Strasbourg, France under the directorship of Dr Christian Gachet. Dr Senis takes a multidisciplinary approach in his research, investigating how tyrosine phosphatases work in conjunction with tyrosine kinases to regulate megakaryocyte and platelet activation, with the overall objective of identifying novel drug targets and therapies for the treatment of myeloproliferative neoplasms, myelofibrosis and improvement of transfusion medicine.